Two of our experts, David Heal and Sharon Smith, have recently been editors of a Special Issue of Neuropharmacology on psychedelic drugs.
Psychedelics: New Doors, Altered Perceptions. Edited by: David J Heal, Sharon L Smith, Jack Henningfield, Bruno G. Frenguelli and David J Nutt. Neuropharmacology Volume 142, pages 1-276 (November 2018).
The Special Issue celebrates the pivotal discovery of LSD and reviews the growing evidence that psychedelic drugs could have value in treatment of a range of psychiatric conditions. This major body of work in an exciting new field contains 14 reviews by leading world experts and 6 articles on original research findings. Topics include: basic pharmacology, therapeutic evaluation in psychiatric disorders, brain imaging, drug development and abuse liability assessment. Click here for further details.
In addition to the editorial, we have contributed a review on the non-clinical assessment of the drug abuse liability of psychedelic drugs.
Psychedelics – Re-opening the doors of perception. Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL. Neuropharmacology. 2018 Nov; 142:1-6. doi: 10.1016/j.neuropharm.2018.08.024. Epub 2018 Aug 23.
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Heal DJ, Gosden J, Smith SL. Neuropharmacology. 2018 Nov; 142: 89-115. doi: 10.1016/j.neuropharm.2018.01.049. Epub 2018 Feb 8.
Please contact us to learn more about our non-clinical models for predicting the risk of abuse and/or dependence of centrally-acting compounds.